Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors. (CTKI258A2120)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: October 2, 2012
Last updated: November 4, 2014
Last verified: November 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2014
  Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)